Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Medizinische Klinik (Munich, Germany : 1983)|May 16, 2000
[Is homocysteine a risk factor for coronary heart disease in patients with terminal renal failure?]A Klusmann, K Ivens, P Schadewaldt, et al.
Journal of Inherited Metabolic Disease|January 1, 1990
On the mechanism of L-alloisoleucine formation: studies on a healthy subject and in fibroblasts from normals and patients with maple syrup urine diseaseP Schadewaldt, H W Hammen, C Dalle-Feste, et al.
Acta Paediatrica (Oslo, Norway : 1992)|January 23, 1999
Diurnal changes in plasma amino acids in maple syrup urine diseaseB Schwahn, U Wendel, P Schadewaldt, et al.
Journal of Inherited Metabolic Disease|October 26, 2006
Variant maple syrup urine disease (MSUD)--the entire spectrumE Simon, N Flaschker, P Schadewaldt, et al.
Journal of Inherited Metabolic Disease|September 3, 1999
Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine diseaseP Schadewaldt, H W Hammen, A C Ott, et al.
Journal of Inherited Metabolic Disease|February 24, 2001
Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantationA Bodner-Leidecker, U Wendel, J M Saudubray, et al.
Clinical Chemistry|October 3, 1999
Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine diseaseP Schadewaldt, A Bodner-Leidecker, H W Hammen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 15, 1992
Determination of (S)- and (R)-2-oxo-3-methylvaleric acid in plasma of patients with maple syrup urine diseaseU Wendel, G Even, U Langenbeck, et al.
Pediatric Research|February 16, 2000
Formation of L-alloisoleucine in vivo: an L-[13C]isoleucine study in manP Schadewaldt, A Bodner-Leidecker, H W Hammen, et al.
Pageof 5